EGFR - Articles and news items

Prof Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim

FDA approves Gilotrif™ (afatinib) as first-line treatment for lung cancer patients with EGFR mutations

Industry news, News / 16 July 2013 / Boehringer Ingelheim

First approval for afatinib, the frontrunner from Boehringer Ingelheim’s new oncology pipeline…

Gene to drugs: can expression be the key to new discoveries?

Genomics, Issue 1 2013 / 25 February 2013 / Esther P. Black, College of Pharmacy and Markey Cancer Center, University of Kentucky

Cancer treatment faces a conundrum: a growing lack of therapeutics with lasting effects. The low hanging fruit of the medicinal chemistry orchard seems to have been picked, and modification of existing anti-cancer therapeutics has produced only incremental rewards[1]. Thus, both pharmaceutical companies and academic researchers are left searching for new strategies that will yield novel, long-lasting therapies and methods to rationally utilise existing therapies, alone and in combination, to individualise treatment regimens. The search for novel anti-cancer therapeutics or novel uses for existing drugs can benefit from the maturity of pharmacogenomics to extract genomic information for identification of new targets and therapeutic strategies.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...